Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

6E0Q

The N-terminal domain of PA endonuclease from the influenza H1N1 virus in complex with 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylic acid

Summary for 6E0Q
Entry DOI10.2210/pdb6e0q/pdb
DescriptorPolymerase acidic protein, MANGANESE (II) ION, 4,6-dihydroxy-2-methyl-5-oxocyclohepta-1,3,6-triene-1-carboxylic acid, ... (5 entities in total)
Functional Keywordsinhibitor, endonuclease, influenza, pa domain, hydrolase-hydrolase inhibitor complex, viral protein, hydrolase/hydrolase inhibitor
Biological sourceInfluenza A virus
Total number of polymer chains1
Total formula weight22898.83
Authors
Dick, B.L.,Morrison, C.N.,Cohen, S.M. (deposition date: 2018-07-06, release date: 2018-11-07, Last modification date: 2023-10-11)
Primary citationCredille, C.V.,Dick, B.L.,Morrison, C.N.,Stokes, R.W.,Adamek, R.N.,Wu, N.C.,Wilson, I.A.,Cohen, S.M.
Structure-Activity Relationships in Metal-Binding Pharmacophores for Influenza Endonuclease.
J. Med. Chem., 61:10206-10217, 2018
Cited by
PubMed Abstract: Metalloenzymes represent an important target space for drug discovery. A limitation to the early development of metalloenzyme inhibitors has been the lack of established structure-activity relationships (SARs) for molecules that bind the metal ion cofactor(s) of a metalloenzyme. Herein, we employed a bioinorganic perspective to develop an SAR for inhibition of the metalloenzyme influenza RNA polymerase PA endonuclease. The identified trends highlight the importance of the electronics of the metal-binding pharmacophore (MBP), in addition to MBP sterics, for achieving improved inhibition and selectivity. By optimization of the MBPs for PA endonuclease, a class of highly active and selective fragments was developed that displays IC values <50 nM. This SAR led to structurally distinct molecules that also displayed IC values of ∼10 nM, illustrating the utility of a metal-centric development campaign in generating highly active and selective metalloenzyme inhibitors.
PubMed: 30351002
DOI: 10.1021/acs.jmedchem.8b01363
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.35 Å)
Structure validation

238268

数据于2025-07-02公开中

PDB statisticsPDBj update infoContact PDBjnumon